UA82845C2 - Use of vasopeptidase inhibitors in the treatment of nephropathy - Google Patents

Use of vasopeptidase inhibitors in the treatment of nephropathy

Info

Publication number
UA82845C2
UA82845C2 UA2005000743A UA2005000743A UA82845C2 UA 82845 C2 UA82845 C2 UA 82845C2 UA 2005000743 A UA2005000743 A UA 2005000743A UA 2005000743 A UA2005000743 A UA 2005000743A UA 82845 C2 UA82845 C2 UA 82845C2
Authority
UA
Ukraine
Prior art keywords
diabetic
nephropathy
treatment
vasopeptidase inhibitors
syndome
Prior art date
Application number
UA2005000743A
Other languages
English (en)
Inventor
Wolfgang Linz
Marcus Bleich
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UA82845C2 publication Critical patent/UA82845C2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2005000743A 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy UA82845C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (fr) 2002-06-28 2003-06-13 Utilisation d'inhibiteurs de la vasopeptidase dans le traitement d'une nephropathie

Publications (1)

Publication Number Publication Date
UA82845C2 true UA82845C2 (en) 2008-05-26

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2005000743A UA82845C2 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Country Status (38)

Country Link
US (2) US6930103B2 (fr)
EP (1) EP1519732B1 (fr)
JP (1) JP4564354B2 (fr)
KR (1) KR101072235B1 (fr)
CN (1) CN100366254C (fr)
AR (1) AR040343A1 (fr)
AT (1) ATE548040T1 (fr)
AU (1) AU2003280440B2 (fr)
BR (1) BR0312250A (fr)
CA (1) CA2490277C (fr)
CR (1) CR7667A (fr)
CY (1) CY1112905T1 (fr)
DE (1) DE10229180A1 (fr)
DK (1) DK1519732T3 (fr)
EC (1) ECSP045513A (fr)
ES (1) ES2383889T3 (fr)
HN (1) HN2003000193A (fr)
HR (1) HRP20041212B1 (fr)
IL (2) IL165935A0 (fr)
MA (1) MA27281A1 (fr)
MX (1) MXPA04012230A (fr)
NO (1) NO334811B1 (fr)
NZ (1) NZ537480A (fr)
OA (1) OA12871A (fr)
PA (1) PA8576501A1 (fr)
PE (1) PE20040582A1 (fr)
PL (1) PL218070B1 (fr)
PT (1) PT1519732E (fr)
RS (1) RS52478B (fr)
RU (1) RU2336080C2 (fr)
SI (1) SI1519732T1 (fr)
SV (1) SV2004001560A (fr)
TN (1) TNSN04262A1 (fr)
TW (1) TWI326215B (fr)
UA (1) UA82845C2 (fr)
UY (1) UY27869A1 (fr)
WO (1) WO2004002492A1 (fr)
ZA (1) ZA200409382B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (fr) * 1990-10-18 2002-04-02 Timothy P. Burkholder Derives de mercaptoacetylamide utiles comme inhibiteurs de l'encephalinase et de l'ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DK0589037T3 (da) * 1991-03-01 1996-09-16 Zeria Pharm Co Ltd Indanderivat og thromboxanantagonist indeholdende samme
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
AU668707B2 (en) * 1992-02-14 1996-05-16 Merrell Pharmaceuticals Inc. Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
ATE189392T1 (de) * 1994-03-24 2000-02-15 Merrell Pharma Inc Hypocholesterolemische, antiatherosklerotische und hypotriglyceridemische verwendung von aminoacetylmercapto derivaten
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
CA2241856C (fr) 1995-12-27 2006-10-17 Yoshitomi Pharmaceutical Industries Ltd. Agent pour prophylaxis et traitement s'appliquant aux complications de diabetes
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
CN1245404C (zh) * 2001-04-12 2006-03-15 塞诺菲-安万特德国有限公司 巯基乙酰胺衍生物、其制备方法及其用途
WO2003013434A2 (fr) * 2001-08-06 2003-02-20 Genomed, Llc Methodes et compositions destinees au traitement de maladies associees a des taux excessifs d'ace

Also Published As

Publication number Publication date
RU2005102087A (ru) 2005-07-10
PT1519732E (pt) 2012-05-22
KR101072235B1 (ko) 2011-10-12
RU2336080C2 (ru) 2008-10-20
ECSP045513A (es) 2005-03-10
US20050171090A1 (en) 2005-08-04
KR20050013642A (ko) 2005-02-04
TWI326215B (en) 2010-06-21
AU2003280440B2 (en) 2009-07-16
AR040343A1 (es) 2005-03-30
TW200406214A (en) 2004-05-01
WO2004002492A1 (fr) 2004-01-08
PL372992A1 (en) 2005-08-08
ES2383889T3 (es) 2012-06-27
US20040058911A1 (en) 2004-03-25
AU2003280440A1 (en) 2004-01-19
HRP20041212B1 (hr) 2013-06-30
CA2490277A1 (fr) 2004-01-08
EP1519732B1 (fr) 2012-03-07
IL165935A0 (en) 2006-01-15
ATE548040T1 (de) 2012-03-15
US6930103B2 (en) 2005-08-16
DK1519732T3 (da) 2012-06-18
HRP20041212A2 (en) 2005-06-30
SV2004001560A (es) 2004-02-26
PA8576501A1 (es) 2004-02-07
PE20040582A1 (es) 2004-10-18
CY1112905T1 (el) 2016-04-13
MXPA04012230A (es) 2005-02-25
HN2003000193A (es) 2004-10-27
CN1665512A (zh) 2005-09-07
OA12871A (en) 2006-09-15
RS52478B (sr) 2013-02-28
NO20050425L (no) 2005-01-25
BR0312250A (pt) 2005-04-26
DE10229180A1 (de) 2004-01-29
UY27869A1 (es) 2003-12-31
JP4564354B2 (ja) 2010-10-20
TNSN04262A1 (en) 2007-03-12
US7514423B2 (en) 2009-04-07
MA27281A1 (fr) 2005-04-01
JP2005533815A (ja) 2005-11-10
CN100366254C (zh) 2008-02-06
NO334811B1 (no) 2014-06-02
CR7667A (es) 2005-06-16
PL218070B1 (pl) 2014-10-31
ZA200409382B (en) 2006-01-25
HK1079435A1 (zh) 2006-04-07
RS100704A (sr) 2007-02-05
NZ537480A (en) 2005-11-25
CA2490277C (fr) 2011-11-01
SI1519732T1 (sl) 2012-05-31
IL165935A (en) 2010-12-30
EP1519732A1 (fr) 2005-04-06

Similar Documents

Publication Publication Date Title
MX2009005048A (es) Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
WO2008011453A3 (fr) HÉTÉROCYCLES AROMATIQUES D'AZOLE SUBSTITUÉS, UTILISÉS EN TANT QU'INHIBITEURS DE LLβ-HSD-1
EA011086B9 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
MX2009012708A (es) Derivados de piridazinona.
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
UA95798C2 (ru) Производные циклогексилпиразоллактама как ингибиторы 11-бета-гидроксистероиддегидрогеназы 1
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
UA89040C2 (ru) Замещенные глюкопиранозилом бензольные производные, лекарственное средство, которое содержит эти соединения
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2010003759A (es) Derivados de piridina utiles como activadores de glucocinasa.
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2010003368A (es) Derivados de imidazol.
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2007006284A (es) Acidos biariloximetilarenocarboxilicos.
CA2659376C (fr) 2,4-diaminoquinazolines contre l'amyotrophie spinale
MY142252A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
TW200744593A (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
TW200407133A (en) Novel PPARα and PPARγ agonists
MX2010003071A (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.